Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models.
Jiemiao HuAlexander J LazarDavis IngramWei-Lien WangWendong ZhangZhiliang JiaDristhi RagoonananJian WangXueqing XiaKris MahadeoRichard GorlickShulin LiPublished in: Journal for immunotherapy of cancer (2024)
This study unveiled a novel therapy-attIL12-T cells-for targeting CAFs/ECM. These findings are highly relevant to humans because CAFs are abundant in human osteosarcoma.